Focused next-generation sequencing (NGS) panel to assess 15 commonly mutated genes in solid tumors with one simple and rapid workflow.
Assay time
Hands-on time
Input quantity
TruSight Tumor 15 is an NGS assay that assesses 15 commonly mutated genes in solid tumors.
Content is carefully selected to include genes and gene regions cited by industry organizations and informed by independent consortia publications and late-stage pharmaceutical research. Content includes single nucleotide variants (SNVs) and indels with demonstrated involvement in solid tumors.
The TruSight Tumor 15 assesses 15 genes in a simple, rapid workflow that replaces single, iterative gene testing with polymerase chain reaction (PCR). Analyze data with on-instrument reporting software or the TruSight Tumor 15 BaseSpace Sequence Hub App.
Go from DNA to data in ~36 hours with only 3.5 hours of hands-on time. Maximize sample success rates across multiple tumor types to conserve limited samples and resources.
| Assay time | 7 hr |
|---|---|
| Automation details | Explore available automation methods |
| Cancer type | Pan-cancer, Solid tumor |
| Content specifications | Amplifies 250 amplicons from 15 genes associated with solid tumors |
| Description | NGS assay for 15 commonly mutated genes in solid tumors using 20 ng DNA. |
| Hands-on time | 3.5 hr |
| Input quantity | 20 ng FFPE DNA |
| Instruments | MiSeq System, MiSeqDx in Research Mode, MiniSeq System |
| Method | Targeted DNA sequencing, Amplicon sequencing |
| Multiplexing | 1-24-plex |
| Nucleic acid type | DNA |
| Specialized sample types | FFPE tissue |
| Species category | Human |
| Technology | Sequencing |
| Variant class | Somatic variants, Insertions-deletions (indels) |
Requires purchase of either a TruSight Tumor 15 MiSeq or MiniSeq Kit, or purchase of TruSight Tumor 15 library prep only. All products are sufficient for 24 samples. If opting to purchase TruSight Tumor 15 library prep only, you will also need to separately purchase sequencing reagents for your system.
The TruSight Tumor 15 MiSeq Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files
TruSight Tumor 15 is a comprehensive workflow solution that assesses somatic variants in 15 genes commonly associated with solid tumors in a single assay, enabling labs to use the power of NGS to focus on genes most likely to play a role in tumorigenesis and confidently analyze low-frequency variants from FFPE DNA.
TruSight Tumor 15
| Instrument | Recommended number of samples | Read length |
|---|---|---|
| MiniSeq System | Samples per run: mid output: 2-3, high output: 8 (based on 93.5% of the bases covered at 500x minimum) |
2 × 150 bp (max recommended) |
| MiSeq System | 8 samples per run with v3 reagents (based on 93.5% of the bases covered at 500x minimum) |
2 × 151 bp (max recommended) |
NGS-based cancer sequencing methods provide more information in less time compared to single-gene and array-based approaches.
Pathology and clinical cancer research
Our clinical cancer research solutions deliver accurate genomic information, and enable labs to analyze multiple genes in a single test.
Ultra-deep sequencing of PCR amplicons enables analysis of specific genomic regions of interest. Learn more about amplicon sequencing and find comprehensive solutions.
| TruSight Tumor 15 | TruSight Tumor 170 | |
|---|---|---|
| Assay time | 7 hr | ~2 days |
| Automation details | Explore available automation methods | Explore available automation methods |
| Cancer type | Pan-cancer, Solid tumor | Solid tumor |
| Content specifications | Amplifies 250 amplicons from 15 genes associated with solid tumors | Probes enrich for full coding sequences of 170 genes. Calls single nucleotide variants, small insertions, and deletions in 151 genes, amplifications in 59 genes, and fusions plus splice variants in 55 genes. |
| Description | NGS assay for 15 commonly mutated genes in solid tumors using 20 ng DNA. | Perform comprehensive somatic variant detection research in solid tumors using variant calling information from both DNA and RNA. |
| Hands-on time | 3.5 hr | ~10.5 hr |
| Input quantity | 20 ng FFPE DNA | 40 ng DNA and/or RNA |
| Instruments | MiSeq System, MiSeqDx in Research Mode, MiniSeq System | NextSeq 550 System, NextSeq 500 System, HiSeq 2500 System |
| Method | Targeted DNA sequencing, Amplicon sequencing | Targeted DNA sequencing, Targeted RNA sequencing, Target enrichment |
| Multiplexing | 1-24-plex | Up to 32-plex for DNA using both index sets, up to 16-plex for RNA |
| Nucleic acid type | DNA | DNA, RNA |
| Specialized sample types | FFPE tissue | Low-input samples, FFPE tissue |
| Species category | Human | Human |
| Technology | Sequencing | Sequencing |
| Variant class | Somatic variants, Insertions-deletions (indels) | Gene fusions, Somatic variants, Structural variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) |
Library Prep and Array Kit Selector
Find the right sequencing library preparation kit or microarray for your needs. Filter by method, species, and more. Compare, share, and order kits.
The TruSight Tumor 15 assay uses a multiplex PCR approach, resulting in high accuracy and sensitivity.
| TruSight Tumor 15 Gene List | ||
|---|---|---|
| AKT1 | GNA11 | NRAS |
| BRAF | GNAQ | PDGFRA |
| EGFR | KIT | PIK3CA |
| ERBB2 | KRAS | RET |
| FOXL2 | MET | TP53 |
TruSight Tumor 15 MiSeq Kit
OP-101-1001
Includes 1 library prep kit and 3 MiSeq reagents sufficient for 24 samples.
List Price:
Discounts:
TruSight Tumor 15 (Library Prep Only)
OP-101-1002
Includes 1 library prep kit sufficient for 24 samples.
List Price:
Discounts:
TruSight Tumor 15 MiniSeq Kit
20005610
Includes 1 library prep kit and 3 MiniSeq reagents sufficient for 24 samples.
List Price:
Discounts:
Showing of
Product
Qty
Unit Price
Product
Catalog ID
Quantity
Unit price
TruSight Tumor 15 is supported on the MiniSeq System and MiSeq System (v3 chemistry), as well as on the MiSeqDx Instrument (in Research Mode; v3 chemistry). Sequencing on other Illumina systems is possible but has not been tested.
The following thermal cyclers are recommended for use with the TruSight Tumor 15 kit. Follow the recommended ramp rate setting listed in the TruSight Tumor 15 Reference Guide.
Bio-Rad C1000
Bio-Rad S1000
Applied Biosystems GeneAmp PCR System 9700
Applied Biosystems Veriti Thermal Cycler
Eppendorf Mastercycler ep Gradient
Eppendorf Mastercycler ep Gradient-S
Bio-Rad C1000, Applied Biosystems GeneAmp PCR System 9700, and Eppendorf MasterCycler ep Gradient were qualified internally
TruSight Tumor 15 targets 15 commonly mutated genes in solid tumors using amplicon sequencing and targeted DNA sequencing on the MiniSeq, MiSeq, and MiSeq Dx (v3 chemistry) Systems. TruSight Tumor 170 targets 170 genes using target enrichment and targeted DNA and RNA sequencing on the NextSeq 500 and NextSeq 550 Systems.
Yes, you may view a sample run and a sample project. A BaseSpace Sequence Hub login is required to access this data.
Advanced chemistry, optics, and informatics combine to deliver exceptional speed and data quality, outstanding throughput and scalability.
Optimized reagent kit that provides increased cluster density and read length, improving sequencing quality scores compared to earlier versions.
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
A fast, integrated workflow for preparing libraries for use in a wide range of sequencing applications.
Reagent v2.5 kits use a resilient flow cell that maintains starting fluorescent intensity, improving stability and performance compared to earlier versions.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.
Target 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types, including blood, bone marrow, and FFPE tissue.
1. Data calculations on file. Illumina, Inc. 2016.
Reach out for information about our products and services, or get answers to questions about our technology.
Your email address is never shared with third parties.
